Day One Bio Q1 2025 Update: R&D, Revenue Details
Ticker: DAWN · Form: 10-Q · Filed: May 6, 2025 · CIK: 1845337
Sentiment: neutral
Topics: 10-Q, financials, biopharmaceutical, R&D
TL;DR
Day One Bio's Q1 2025 10-Q is out. Shows R&D spend and revenue. Check Mabcare deal.
AI Summary
Day One Biopharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance, including research and development expenses and sales revenue. It also mentions specific agreements like the Mabcare License Agreement and equity incentive plans.
Why It Matters
This filing provides investors with a quarterly update on Day One Biopharmaceuticals' financial health and operational progress, crucial for assessing investment value.
Risk Assessment
Risk Level: medium — Biopharmaceutical companies often face high risks due to the nature of drug development and regulatory hurdles.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Covers the first quarter of 2025)
- 2024-01-01 — Prior Year Start Date (For comparative financial data)
Key Players & Entities
- Day One Biopharmaceuticals, Inc. (company) — Filer of the 10-Q
- Mabcare License Agreement (company) — Specific agreement mentioned
- 2000 Sierra Point Parkway, Suite 501, Brisbane, CA 94005 (location) — Company business and mailing address
FAQ
What were Day One Biopharmaceuticals' total revenues for the quarter ending March 31, 2025?
The filing indicates 'SalesRevenueNetMember' for the period 2025-01-01 to 2025-03-31, but specific dollar amounts are not provided in this excerpt.
What were the research and development expenses for the first quarter of 2025?
The filing references 'ResearchAndDevelopmentExpenseMember' for the period 2025-01-01 to 2025-03-31, but the exact figure is not detailed in this section.
Does the company have any significant customer concentration risk?
Yes, the filing mentions 'ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesMember' and 'OneCustomerMember' for the period 2025-01-01 to 2025-03-31, indicating potential risk.
What is the status of the Mabcare License Agreement?
The Mabcare License Agreement is mentioned in relation to 'ResearchAndDevelopmentExpenseMember' for the period 2025-01-01 to 2025-03-31, suggesting ongoing activity or costs associated with it.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding Day One Biopharmaceuticals, Inc. (DAWN).